Golechha Bioscience Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 13-12-2024
- Paid Up Capital ₹ 2.50 M
as on 13-12-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.06 Cr
as on 13-12-2024
- Revenue 51.26%
(FY 2021)
- Profit -17.32%
(FY 2021)
- Ebitda 12.53%
(FY 2021)
- Net Worth 9.33%
(FY 2021)
- Total Assets -0.12%
(FY 2021)
About Golechha Bioscience
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.06 Cr.
Nilesh Golechha, Bhushan Golechha, Nikhil Jogad, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999MH2013PTC245892
- Company No.
245892
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Wardha, Maharashtra, India
- Telephone
- Email Address
- Social Media-
What products or services does Golechha Bioscience Private Limited offer?
Golechha Bioscience Private Limited offers a wide range of products and services, including Health Drinks, Glucose Powder, Instant Drink Mix, Coconut Water Powder.
Who are the key members and board of directors at Golechha Bioscience?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhushan Golechha  | Director | 19-Jul-2013 | Current |
| Nilesh Golechha | Director | 19-Jul-2013 | Current |
| Nikhil Jogad | Director | 19-Jul-2013 | Current |
| Rajkumar Golechha | Director | 19-Jul-2013 | Current |
Financial Performance of Golechha Bioscience.
Golechha Bioscience Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 51.26% increase. The company also saw a substantial fall in profitability, with a 17.32% decrease in profit. The company's net worth moved up by a moderate rise of 9.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Golechha Bioscience?
In 2021, Golechha Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Feb 2024 | ₹1.10 M | Open |
Others Creation Date: 19 Nov 2014 | ₹9.53 M | Open |
How Many Employees Work at Golechha Bioscience?
Unlock and access historical data on people associated with Golechha Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Golechha Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Golechha Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
